Aytu Bioscience: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value
Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.
Your own DCF model
A full discounted-cash-flow model of Aytu Bioscience, started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Biotechnology
Multiples of its companies with a market value at most 60 days old, times Aytu Bioscience's own figures of FY2026.
| Multiple | Peers (25th / median / 75th) | Aytu Bioscience | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| Price to sales | 2.2× / 5.0× / 10.1× | 0.4× | revenue $58 M | $129 M to $581 M | 85 |
| Price to book | 3.1× / 4.5× / 12.3× | 0.6× | book equity $35 M | $109 M to $435 M | 70 |
Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.
Against its own history
Aytu Bioscience's multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
Price to sales
0.4×Now above its median of 0.3×; range 0.1× to 3.7× over 30 months.
Price to book
0.6×Now below its median of 0.7×; range 0.2× to 3.1× over 30 months.
as of Oct 26, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 26, 2026.
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2026to Jun 30, 2026 | $58 M | $-14 M | $3 M | $0 M | $3 M | $-17 M | SEC annual report (10-K, 20-F) |
| FY2025to Jun 30, 2025 | $66 M | $-14 M | $-2 M | $0 M | $-2 M | $-20 M | SEC annual report (10-K, 20-F) |
| FY2024to Jun 30, 2024 | $65 M | $-16 M | $-1 M | $0 M | $-2 M | $-9 M | SEC annual report (10-K, 20-F) |
| FY2023to Jun 30, 2023 | $107 M | $-17 M | $-5 M | — | — | $-8 M | SEC annual report (10-K, 20-F) |
| FY2022to Jun 30, 2022 | $97 M | $-109 M | $-29 M | $0 M | $-29 M | $-4 M | SEC annual report (10-K, 20-F) |
| FY2021to Jun 30, 2021 | $66 M | $-58 M | $-26 M | $2 M | $-28 M | — | SEC annual report (10-K, 20-F) |
Each figure as filed; the full statements with every line and its filing are on the company page. Market value $21 M on Oct 26, 2026.
How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.